Johnson & Johnson, a global healthcare company, has recently been in the spotlight due to controversies surrounding their talc products....
Johnson & Johnson, a leading pharmaceutical company, continues to make waves in the industry with its latest submission of sNDA for the schizophrenia drug CAPLYTA to the FDA....
Johnson & Johnson, the renowned medical technology company, continues to be at the forefront of innovation in the industry....
Mark Dickinson, the leader of Johnson & Johnson Neurovascular, has announced his departure from the company....
Mark Dickinson, the leader of Johnson & Johnson Neurovascular, is leaving the company, according to sources....
Johnson & Johnson's MedTech division has received clearance from the FDA for its enhanced robotic-assisted bronchoscopy system....
Johnson & Johnson MedTech, a subsidiary of Johnson & Johnson, has appointed a new leader for its electrophysiology and neurovascular group....
Johnson & Johnson has been investing in research and development for decades in order to find effective treatments for inflammatory bowel disease (IBD)....
Johnson & Johnson (JNJ) has shown an impressive 8.9% increase in its stock price since the release of its last earnings report....
Johnson & Johnson (JNJ) has been at the forefront of medical technology, constantly innovating and developing breakthrough surgical devices that not only speed up the healing process but also save lives....
In a major move to bolster its presence in the mental health sector, pharmaceutical giant JNJ Johnson & Johnson has announced its acquisition of Intra-Cellular Therapies for a staggering $14.6 billion....
Pharmaceutical giant AbbVie Inc. (ABBV) experienced a significant drop in stock prices today, following disappointing results from their latest schizophrenia drug trials....
Shares of AbbVie Inc. (ABBV) took a hit today after the results of the company's schizophrenia drug trials fell short of expectations....
Johnson & Johnson, a leading pharmaceutical company, continues to make waves in the industry with its latest submission of sNDA for the schizophrenia drug CAPLYTA to the FDA....
AbbVie Inc. (ABBV) experienced a decline in stock value today after disappointing results from its schizophrenia drug trials. However, some investors may see this as a buying opportunity....